Novo Nordisk Suffers Blow in Brazil as Court Rejects Bid to Block 'Local Ozempic'

Global healthcare investors tracking the blockbuster weight-loss and diabetes market just received a stark reminder of how quickly post-patent competition can erode a monopoly. While US patent protections shield the massive cash flows of major pharmaceutical companies for years to come, international markets are already transforming into low-cost battlegrounds.

On July 31, 2026, Brazil’s Federal Regional Court of the 2nd Region (TRF-2) denied an injunction request by Danish pharmaceutical giant Novo Nordisk to block local drugmaker EMS from using the trademark "Ozivy" for its newly launched generic semaglutide. Novo Nordisk had argued that the name "Ozivy" unfairly combined the prefix of Ozempic and the suffix of Wegovy to create an undue, parasitic association with its proprietary brands.

The legal setback follows the expiration of Novo Nordisk's core semaglutide patent in Brazil on March 20, 2026, which unleashed a wave of local generic registrations. Brazil's health regulator, Anvisa, approved Ozivy in May 2026 as the country's first synthetic semaglutide pen. EMS, the largest pharmaceutical company in Brazil, priced its alternative at roughly 30% to 50% below the cost of original Ozempic, targeting a massive and highly receptive consumer base.

In his ruling, Federal Judge José Eduardo Nobre Matta stated that suspending a registered trademark shortly after its commercial launch would cause irreversible damage to the local manufacturer. The judge also noted that public association between the two products is a natural consequence of Ozivy being the first generic competitor to hit the market after the patent expired, rather than a result of trademark infringement.

While Novo Nordisk continues to operate its massive local manufacturing plant in Montes Claros, Brazil, to supply global markets, it now faces a rapidly crowding domestic arena. Following the May 2026 approval of EMS's Ozivy, Anvisa has cleared several other local semaglutide alternatives from competitors like Hypera. The sudden influx of cheaper options is expected to reshape the pricing dynamics of the GLP-1 market across Latin America's largest economy.

In your brokerage app

For retail investors holding shares of Novo Nordisk, listed in New York as American Depositary Receipts, the Brazilian court decision highlights the geographic limits of the company's pricing power. While US patents protect Novo Nordisk's core portfolio until at least 2031, international revenues face immediate pressure as local courts and regulators pave the way for cheaper, generic alternatives.